IRIS
FASANO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.409
NA - Nord America 3.226
AS - Asia 2.898
SA - Sud America 584
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 4
Totale 10.191
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.158
CN - Cina 1.094
IE - Irlanda 930
SG - Singapore 719
UA - Ucraina 714
SE - Svezia 481
BR - Brasile 461
RU - Federazione Russa 429
FR - Francia 321
VN - Vietnam 303
HK - Hong Kong 244
IN - India 219
TR - Turchia 188
FI - Finlandia 186
DE - Germania 102
IT - Italia 91
GB - Regno Unito 68
AR - Argentina 56
CA - Canada 27
MX - Messico 23
BD - Bangladesh 22
AT - Austria 21
EU - Europa 21
ID - Indonesia 21
ZA - Sudafrica 19
EC - Ecuador 17
IQ - Iraq 15
CZ - Repubblica Ceca 14
PK - Pakistan 13
CO - Colombia 12
NL - Olanda 10
UY - Uruguay 10
VE - Venezuela 10
BE - Belgio 9
ES - Italia 9
EG - Egitto 8
SY - Repubblica araba siriana 8
PY - Paraguay 7
BG - Bulgaria 6
JP - Giappone 6
NP - Nepal 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
KE - Kenya 5
PL - Polonia 5
TT - Trinidad e Tobago 5
SV - El Salvador 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CH - Svizzera 3
IR - Iran 3
JM - Giamaica 3
KZ - Kazakistan 3
PE - Perù 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
AU - Australia 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
KR - Corea 2
LB - Libano 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RO - Romania 2
SN - Senegal 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
ML - Mali 1
MM - Myanmar 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
UG - Uganda 1
Totale 10.191
Salva come PNG Salva come JPEG
Città #
Dublin 928
San Jose 582
Jacksonville 505
Dearborn 317
Singapore 299
Nyköping 298
Nanjing 281
Chandler 249
Hong Kong 241
Ashburn 154
Beijing 154
Wilmington 137
Dong Ket 117
Santa Clara 116
Dallas 109
Nanchang 102
Princeton 102
Lauterbourg 98
Moscow 80
San Mateo 79
Helsinki 78
Ho Chi Minh City 71
The Dalles 61
Shenyang 60
Hebei 52
Kunming 51
Tianjin 44
Hanoi 41
Munich 38
Jiaxing 37
Ann Arbor 35
Changsha 34
Ningbo 29
New York 28
São Paulo 27
Jinan 26
Stevenage 24
Des Moines 23
Zhengzhou 21
Los Angeles 20
Guangzhou 19
Hilden 19
Hangzhou 17
Nuremberg 16
Lanzhou 15
Shanghai 15
Turku 14
Ankara 13
Brno 13
Taizhou 13
Redwood City 12
Rio de Janeiro 12
Vienna 12
Pune 10
Montevideo 9
Quảng Ngãi 9
Woodbridge 9
Brasília 8
Chengdu 8
Foggia 8
Guarulhos 8
Johannesburg 8
Phoenix 8
Brussels 7
Haiphong 7
London 7
Orange 7
San Francisco 7
Baghdad 6
Belo Horizonte 6
Biên Hòa 6
Boardman 6
Boston 6
Campinas 6
Chicago 6
Guayaquil 6
Hefei 6
Mexico City 6
Montreal 6
Norwalk 6
Ribeirão Preto 6
Tokyo 6
Toronto 6
Al Mansurah 5
Augusta 5
Bari 5
Bogotá 5
Buenos Aires 5
Cape Town 5
Changchun 5
Curitiba 5
Frankfurt am Main 5
Medellín 5
Paris 5
Porto Alegre 5
Warsaw 5
Atlanta 4
Belém 4
Chandigarh 4
Dhaka 4
Totale 6.229
Salva come PNG Salva come JPEG
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 209
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 181
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 164
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 150
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 147
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 132
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 130
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 128
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 127
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 127
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 126
Flares during long-term entecavir therapy in chronic hepatitis B 123
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 122
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 120
A proposito di epatite B. News da EASL 2008. 120
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 120
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 119
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 118
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 116
Chronic hepatitis B: Advances in treatment. 116
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 115
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 114
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 113
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 112
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 110
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 109
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 108
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 108
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 107
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 106
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 105
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 105
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 104
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 103
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 102
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 101
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 101
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 101
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 100
Malattie causate da Elminti 100
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 100
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 99
Come trattare il paziente con non risposta o risposta virologica parziale 99
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 99
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 98
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 98
Reply. 97
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 97
Nuove strategie di trattamento 97
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 97
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 94
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 94
Definizione delle resistenze e metodiche di laboratorio 94
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 94
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 92
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 92
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 92
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 92
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 91
Mutations selected during lamivudine therapy may predispose to adefovir resistance 91
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 90
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 90
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 90
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 90
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 89
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 89
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 87
Resistance profile of entecavir in patients with chronic hepatitis B 87
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 87
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 86
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 86
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 85
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 85
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 85
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 85
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 84
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 83
Epatite B e Immigrazione 83
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 83
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 83
HBV e migranti: risultati di uno studio multicentrico SIMIT 82
Epatite acuta C in pazienti in trattamento emodialitico periodico. 82
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 82
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 80
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 80
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 79
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 79
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 78
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 78
HBV and immigrants: a SIMIT multicenter cross-sectional study 76
Entecavir in “real-life”: risultati dello studio VIRGIL 76
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 76
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 75
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 74
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 72
Intraoperative ultrasound: “Alternative eye” in lymph nodal dissection in non-small cell lung cancer 72
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 71
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 71
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 69
Epatiti virali croniche e gravidanza 69
Totale 9.974
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 0 0 0 0 0 0 150
2021/2022554 74 8 7 9 73 32 15 54 66 68 16 132
2022/20231.856 237 91 58 76 53 138 2 126 1.021 17 21 16
2023/2024189 34 10 7 13 18 41 26 8 3 3 1 25
2024/20251.331 68 3 9 14 8 187 201 74 384 63 180 140
2025/20262.662 152 142 458 569 70 66 471 241 200 119 50 124
Totale 10.491